8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 2, 2006

BIOMET, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Indiana	0-12515	35-1418342
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

56 East Bell Drive

Warsaw, Indiana 46582

(Address of Principal Executive Offices, including  Zip Code)

(574) 267-6639

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01  Other Events.

This Form 8-K is being filed to provide the information set forth in Biomet, Inc.’s November 2, 2006 press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The press release contains certain statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Although Biomet believes that the assumptions, on which the forward-looking statements contained in the press release are based, are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance that the forward-looking statements contained in the press release will prove to be accurate. The inclusion of a forward-looking statement in the press release should not be regarded as a representation by Biomet that Biomet’s objectives will be achieved.

Item 9.01 Financial Statement and Exhibits.

(d) Exhibits.

Exhibit 99.1   Press Release issued November 2, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOMET, INC.
/s/ Gregory D. Hartman
By:	Gregory D. Hartman
Its:	Senior Vice President - Finance
	(Principal Financial Officer)

Date: November 2, 2006

2

EX-99.1

Exhibit 99.1

Biomet Press Release

WARSAW, Ind.—(BUSINESS WIRE)—Biomet, Inc. (NASDAQ:BMET - News) announced on April 6, 2006, that Morgan Stanley & Co. Incorporated was retained to assist Biomet in exploring strategic alternatives and, consistent with this announcement, Biomet continues to assess all of its strategic alternatives. While Biomet has had a preliminary discussion with Smith & Nephew plc. as Smith & Nephew stated in a press release earlier today, Biomet has not made a determination that it is in Biomet’s best interests for it to engage in a transaction with any third party.

Interim President and CEO Daniel P. Hann said, “Biomet is focused on implementing its strategic plan for growth and expansion. Our market leading products, superb team members, sales personnel and customers are the greatest source of value to our business.”

Biomet also stated that it does not expect to disclose developments with respect to its exploration of strategic alternatives unless required.

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. The Company’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.

For further information contact Greg W. Sasso, Senior Vice President, Corporate Development and Communications at (574) 372-1528 or Barbara Goslee, Manager, Corporate Communications at (574) 372-1514.

# # #